Accepted for Publication: January 23, 2019.
Published Online: May 13, 2019. doi:10.1001/jamainternmed.2019.0306
Correction: This article was corrected on June 10, 2019, to add the Open Access paragraph to the acknowledgments section and again on July 1, 2019, to fix errors in the caption to Figure 2.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Wentzensen N et al. JAMA Internal Medicine.
Corresponding Author: Nicolas Wentzensen, MD, PhD, MS, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 9609 Medical Center Dr, Room 6-E448, Bethesda, MD 20892 (wentzenn@mail.nih.gov).
Author Contributions: Drs Wentzensen and Clarke had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Wentzensen, Castle, Schiffman, Lorey.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Wentzensen, Bremer, Poitras, Tokugawa, Castle, Schiffman.
Critical revision of the manuscript for important intellectual content: Wentzensen, Clarke, Goldhoff, Castle, Schiffman, Kingery, Grewal, Locke, Kinney, Lorey.
Statistical analysis: Wentzensen, Clarke, Bremer, Poitras, Castle, Schiffman.
Obtained funding: Wentzensen, Schiffman.
Administrative, technical, or material support: Wentzensen, Poitras, Tokugawa, Goldhoff, Schiffman, Kingery, Grewal, Kinney, Lorey.
Supervision: Wentzensen.
Conflict of Interest Disclosures: Dr Wentzensen reported being employed by the National Cancer Institute (NCI), which has received cervical cancer screening assays in-kind or at reduced cost from BD and Roche for studies that Dr Wentzensen is conducting. Dr Goldhoff reported receiving grants from the National Institutes of Health (NIH)/NCI during the conduct of the study. Dr Castle reported receiving cervical screening tests and diagnostics from Roche, Becton Dickinson, Cepheid, and Arbor Vita Corp at a reduced cost or no cost for research. Dr Schiffman reported being employed by the NCI, which has received cervical cancer screening assays in-kind or at reduced cost from companies involved in cervical screening, including Roche, BD, Qiagen, and MobileODT. Dr Kingery reported receiving grants from the NIH and the NCI during the conduct of the study and receiving grants from the NIH and the NCI outside the submitted work. Dr Grewal reported receiving grants from the NIH and the NCI during the conduct of the study and grants from the NIH and the NCI outside the submitted work. Dr Lorey reported receiving grants from the NIH and the NCI during the conduct of the study and grants from the NIH and the NCI outside the submitted work. No other disclosures were reported.
Additional Information: This article is dedicated to Barbara Fetterman, SCT.
4.Cuschieri
K, Ronco
G, Lorincz
A,
et al. Eurogin roadmap 2017: triage strategies for the management of HPV-positive women in cervical screening programs.
Int J Cancer. 2018;143(4):735-745. doi:
10.1002/ijc.31261PubMedGoogle ScholarCrossref 7.Wright
TC, Stoler
MH, Behrens
CM, Sharma
A, Zhang
G, Wright
TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.
Gynecol Oncol. 2015;136(2):189-197. doi:
10.1016/j.ygyno.2014.11.076PubMedGoogle ScholarCrossref 8.Guan
P, Howell-Jones
R, Li
N,
et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer.
Int J Cancer. 2012;131(10):2349-2359. doi:
10.1002/ijc.27485PubMedGoogle ScholarCrossref 9.Wright
TC
Jr, Stoler
MH, Behrens
CM, Sharma
A, Sharma
K, Apple
R. Interlaboratory variation in the performance of liquid-based cytology: insights from the ATHENA trial.
Int J Cancer. 2014;134(8):1835-1843. doi:
10.1002/ijc.28514PubMedGoogle ScholarCrossref 10.Carozzi
F, Confortini
M, Dalla Palma
P,
et al; New Technologies for Cervival Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial.
Lancet Oncol. 2008;9(10):937-945. doi:
10.1016/S1470-2045(08)70208-0PubMedGoogle ScholarCrossref 11.Carozzi
F, Gillio-Tos
A, Confortini
M,
et al; NTCC working group. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Lancet Oncol. 2013;14(2):168-176. doi:
10.1016/S1470-2045(12)70529-6PubMedGoogle ScholarCrossref 19.Katki
HA, Kinney
WK, Fetterman
B,
et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
Lancet Oncol. 2011;12(7):663-672. doi:
10.1016/S1470-2045(11)70145-0PubMedGoogle ScholarCrossref 20.Wentzensen
N, Fetterman
B, Tokugawa
D,
et al. Interobserver reproducibility and accuracy of p16/Ki-67 dual-stain cytology in cervical cancer screening.
Cancer Cytopathol. 2014;122(12):914-920. doi:
10.1002/cncy.21473PubMedGoogle ScholarCrossref 21.Grabe
N, Lahrmann
B, Pommerencke
T, von Knebel Doeberitz
M, Reuschenbach
M, Wentzensen
N. A virtual microscopy system to scan, evaluate and archive biomarker enhanced cervical cytology slides.
Cell Oncol. 2010;32(1-2):109-119. doi:
10.3233/CLO-2009-0508PubMedGoogle Scholar